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Structural Associations of Symptomatic Knee Osteoarthritis
Laura A. Stoppiello,1 Paul I. Mapp,1 Deborah Wilson,2 Roger Hill,2
Brigitte E. Scammell,1 and David A. Walsh3
Objective. Structural changes of osteoarthritis
(OA) may occur in the absence of pain. In this study, we
aimed to identify histopathologic features that are as-
sociated with symptomatic knee OA.
Methods. Medial tibial plateaus and synovium
samples were obtained at the time of total knee replace-
ment (TKR) surgery for OA (advanced OA group) or
were obtained postmortem from subjects who had not
sought medical attention for knee pain during the last
year of life (non-OA control group). To identify features
of OA, we compared the patients with advanced OA with
the age-matched non-OA controls (n  26 per group).
To identify OA features associated with symptoms, we
compared two additional groups of subjects who were
matched for severity of chondropathy (n  29 per
group): patients undergoing TKR for symptomatic OA
(symptomatic chondropathy group) and postmortem
subjects with similar severity of chondropathy who were
asymptomatic during the last year of life (asymptomatic
chondropathy group). The histologic features of the
samples were graded, and immunoreactivities formacro-
phages (CD68) and nerve growth factor (NGF) in the
synovium were quantified. The cellular localization of
synovial NGF was determined by double immunofluo-
rescence analysis.
Results. Advanced OA cases displayed more se-
vere changes in the synovium (synovitis, increased syno-
vial NGF, and CD68-immunoreactive macrophages)
and cartilage (loss of cartilage surface integrity, loss of
proteoglycan, tidemark breaching, and alterations in
chondrocyte morphology) than did the non-OA controls.
Synovial NGF was localized predominantly to fibro-
blasts and to some macrophages. The symptomatic
chondropathy group displayed greater levels of synovi-
tis, synovial NGF, and loss of cartilage integrity, in
addition to alterations in chondrocyte morphology, than
did the asymptomatic chondropathy group (P < 0.05 for
each comparison).
Conclusion. Synovitis, increased synovial NGF,
alterations in chondrocyte morphology, and loss of
cartilage integrity are features of knee OA that may be
associated with symptoms.
Osteoarthritis (OA) is the most common joint
disease in the elderly population. Pathologic features
include articular cartilage degradation, synovial inflam-
mation, osteophytes, and bone marrow lesions. Pain is
the main reason sufferers seek clinical assistance. Pa-
tients with end-stage OA may eventually benefit from
total knee replacement (TKR) surgery.
Although joint pathology makes an important
contribution to OA pain, the precise relationship be-
tween pain and structural pathology is not entirely clear
(1,2). Radiographic features of OA are often weakly
associated with pain, suggesting that structural, cellular,
or biochemical changes that directly mediate pain may
not be easily detected on radiographs. Imaging studies
have indicated possible associations between pain and
synovitis (3–6) or subchondral changes (6–9), but asso-
ciations with histopathology have not been explored in
detail. Such studies have previously been limited by age
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differences between OA patients and normal controls
and by limited access to joint tissue from people with
OA whose pain is less than that which would lead them
to undergo joint replacement surgery.
Synovitis may contribute to OA knee pain. The
cause of synovitis in OA is incompletely understood, but
has been observed in both early (10) and late disease
(11). Synovitis may mediate pain through the production
of factors that sensitize or activate sensory nerves.
Recent evidence has suggested an important role
of nerve growth factor (NGF) in mediating inflamma-
tory pain through increasing nociceptor sensitivity or fa-
cilitating sensory nerve growth (12). NGF blockade was
shown to improve the degree of pain from knee OA
(13–15), indicating a causal link between NGF and OA
pain.
NGF is elevated in a variety of rheumatic dis-
eases, particularly in the synovial fluid of patients with
inflammatory arthritis (16,17). NGF is expressed by
synovial macrophages from patients with rheumatoid
arthritis, spondyloarthritis, and to a lesser extent, in OA
(17), as well as by synovial fibroblasts from patients with
OA (18). However, the expression and cellular profile of
NGF in synovial biopsy samples from people with knee
OA has not been explored in detail. Synovial fibroblasts
can be visualized using immunohistochemistry with anti-
bodies directed against Hsp47, a collagen-specific mo-
lecular chaperone (19). Macrophages can be identified
by the transmembrane glycoprotein CD68 (20).
Our aim in the present study was to first validate
the measurement of histopathologic characteristics of
knee OA by comparing samples obtained at the time of
TKR surgery for OA (advanced OA) with samples
collected postmortem from age-matched non-OA con-
trols. Second, we aimed to identify histopathologic fea-
tures associated with symptomatic knee OA by compar-
ing cases with similar macroscopic chondropathy, half of
whom had sought medical care for knee pain and had
undergone TKR (symptomatic chondropathy) and the
other half had not sought medical care for knee pain but
had died of an unrelated illness (asymptomatic chon-
dropathy). We hypothesized that symptomatic OA is
mediated by specific structural and biochemical changes
within the knee joint, whereas other changes may be
coincidental or even protective.
PATIENTS AND METHODS
Patient samples. The joint tissue repository of the
Arthritis Research UK Pain Centre, which contains samples
from 1,700 subjects, was screened first to select tissues
obtained at the time of TKR for OA (advanced OA group) and
tissues obtained postmortem from age-matched subjects who
had not sought medical attention for knee pain during the last
year of life (non-OA control group) (n  26 per group) and
second to select tissues from patients who had undergone TKR
for symptomatic OA (symptomatic chondropathy group) and
tissues with similar macroscopic chondropathy scores obtained
postmortem from subjects who had not sought medical atten-
tion for knee pain during the last year of life (asymptomatic
chondropathy group) (n  29 per group). One TKR case was
included in both the advanced OA group and the symptomatic
chondropathy group and was therefore counted twice.
Patients undergoing TKR fulfilled the American Col-
lege of Rheumatology classification criteria for OA (21) at
the time of surgery. Subjects from whom samples were ob-
tained postmortem were recently deceased, had no history of
rheumatoid arthritis or pseudogout, and had not previously
sought help for knee pain during the last year of life, as
determined by interviews with the relatives and review of case
notes. Exclusion criteria for non-OA controls consisted of a
history of OA, Heberden’s nodes identified on clinical exami-
nation, macroscopic chondropathy lesions of grade 3 or 4 in
the medial tibiofemoral compartment, or osteophytes on direct
visualization of the dissected knee.
Body mass index (BMI; kg/m2) in the TKR cases was
calculated from measurements of height and weight that were
documented in the cases notes. BMI in the postmortem cases
could not be calculated because height and weight measure-
ments were not available.
Informed consent was obtained from the TKR patients
and from the next of kin of the postmortem subjects. The study
was approved by the UK National Research Ethics Service
(Nottingham Research Ethics Committee 1 [05/Q2403/24] and
Derby Research Ethics Committee 1 [11/H0405/2]).
Sample processing. Midcoronal sections of the middle
one-third of the medial tibial plateau were fixed in neutral-
buffered formalin and then decalcified in 10% EDTA in 10
mM Tris buffer (pH 6.95; at 4°C) prior to embedding in wax.
Surgeons and technicians were instructed to collect synovium
from the medial joint line. Synovial tissues were fixed in
formalin and embedded in wax without decalcification or were
frozen without fixation in melting isopentane and embedded in
OCT mounting medium (Raymond A. Lamb Ltd.).
Macroscopic chondropathy score. Following tissue
harvesting, the articular surfaces of the medial and lateral tibial
plateaus and femoral condyles were evaluated for the extent
and severity of loss of surface integrity by a single assessor
(RH), as described by Walsh et al (22) based on the method of
Ayral et al (23). Briefly, articular surface defects were graded
from 0 (normal, smooth, unbroken surface) to 4 (subchondral
bone exposure), and the proportion of each articular surface
area corresponding to each grade was used to calculate a
chondropathy score (range 0–100). Scores for each of the 4
compartments were summed to give a total tibiofemoral
chondropathy score (range 0–400). Surgical damage precluded
the calculation of macroscopic chondropathy scores for some
TKR cases.
Radiographic OA severity score. Radiographic severity
scores for OA were derived using preoperative posteroanterior
knee radiographs as previously described (22). An atlas of line
drawings of the knee joint was used to grade medial and lateral
joint space narrowing and osteophytes (24). The scores for
joint space narrowing (range 0–6) and osteophytes (range
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0–12) were summed to provide a total radiographic OA
severity score (range 0–18). Radiographs were not available
for postmortem cases.
Histologic assessment and grading. Formalin-fixed
tissue sections (5 m) were stained with hematoxylin and eosin
or, to visualize proteoglycan content in the medial tibial
plateaus, with Safranin O–fast green. Articular cartilage
changes of OA were graded as 4 components according to the
Mankin scoring system (25): cartilage surface integrity was
graded on a scale of 0–6 (where 0  normal and 6  complete
disorganization), tidemark integrity was graded 0 or 1 (where
0  intact and 1  crossed by vessels), chondrocyte morphol-
ogy was graded on a scale of 0–3 (where 0  normal and 3 
hypocellular), and proteoglycan loss was graded on a scale of
0–4 (where 0 normal, no loss of Safranin O staining and 4
complete loss of staining). The presence of subchondral bone
marrow replacement by fibrovascular tissue was assessed in
each case as either present (pathologic) or absent (normal).
Synovial inflammation was graded on a scale of 0–3 (where 0
normal and 3  severe inflammation) by assessing the degree
of synovial lining hyperplasia, inflammatory cell infiltrate, and
cellularity (11).
Immunohistochemistry. Sections of formalin-fixed sy-
novium underwent antigen retrieval (1 mg/ml of pepsin in
0.5M acetic acid at 37°C for 2 hours), incubated with mono-
clonal mouse anti-human CD68 (clone PG-M1; Dako), fol-
lowed by biotinylated horse anti-mouse IgG secondary anti-
body (Vector). NGF immunoreactivity was visualized after
citrate buffer antigen retrieval (90°C for 20 minutes). Sections
were blocked with 5% bovine serum albumin (BSA) containing
goat serum, followed by incubation with rabbit monoclonal
antibody to NGF (clone EP1320Y; Abcam) and biotinylated
goat anti-rabbit IgG secondary antibody (Vector). Visualiza-
tion of both immunoreactivities used avidin–biotin complex
peroxidase (Vector) with nickel-enhanced diaminobenzidine
development (26).
Synovium samples from 3 TKR patients, 3 postmortem
cases with high levels of chondropathy, and 2 non-OA controls
were simultaneously double-stained for NGF and either mac-
rophage or fibroblast markers. Frozen synovial tissue sections
were fixed in 4% paraformaldehyde, followed by acetone and
then were blocked with 5% BSA containing goat serum and
horse serum. Sections were incubated overnight with a mixture
of antibodies directed toward NGF (as above) and either
CD68 (as above) or Hsp47 (M16.10A1; Enzo Life Sciences),
followed by incubation with a mixture of secondary antibodies:
Texas Red–labeled horse anti-mouse IgG and fluorescein-
labeled goat anti-rabbit IgG (Vector). Sections were counter-
Table 1. Clinical and pathologic characteristics of the study groups*
Characteristic
Features of OA Features of symptomatic OA
Non-OA
control
(n  26)
Advanced
OA
(n  26)
Asymptomatic
chondropathy
(n  29)
Symptomatic
chondropathy
(n  29)
Age, years 61 (48–67) 61 (50–67) 71 (66–79) 68 (61–74)†
% male 62 31† 55 55
BMI, kg/m2 NA 32 (29–40) NA 31 (28–37)
Macroscopic chondropathy score (range 0–400) 51 (40–69) NA 199 (177–215)‡ 223 (185–234)‡
Total radiographic score (range 0–18)§ NA 12 (10–13) NA 12 (10–13)
JSN score (range 0–6) NA 5 (4–5) NA 5 (4–5)
Osteophyte score (range 0–12) NA 7.5 (5–8) NA 8 (5.7–8)
Histologic features
Total Mankin score (range 0–14)¶ 5 (3–7) 8 (7–9)# 7 (7–8) 8 (7.5–9)
Cartilage surface integrity (range 0–6) 2 (2–3) 4 (4–4)‡ 4 (3–4) 4 (4–4)†
% with breached tidemark 35 68† 66 67
Proteoglycan loss (range 0–4) 1 (1–1) 1 (1–2)† 1 (1–2) 1 (1–2)
Chondrocyte morphology (range 0–3) 1 (0–3) 2.5 (2–3)† 3 (1.5–3) 3 (2–3)†
% with subchondral bone marrow replacement 0 19 18 32
Synovitis (range 0–3) 0 (0–0) 0 (0–3)† 0 (0–0.25) 2 (0–3)#
Fractional areas**
Macrophage 3.4 (1.8–4.6) 4.8 (3.1–8.7)† 7.4 (4.2–13.2) 13.1 (6.6–15.3)
Nerve growth factor 1.4 (0.4–1.8) 4.0 (1.5–8.3)† 8.7 (5.9–12.4) 12.9 (9.4–18.6)†
* Tissues were obtained at the time of total knee replacement for osteoarthritis (OA) or were obtained postmortem from cadaver donors. Data for
the body mass index (BMI) were available for 23 patients with advanced OA and 20 patients with symptomatic chondropathy. (One patient with TKR
was included in both groups and was therefore counted twice.) Statistical comparisons for the immunohistochemical and histomorphometric data
were not made between the features of OA and the features of symptomatic OA subgroups because staining was carried out in separate experiments.
Except where indicated otherwise, values are the median (interquartile range). NA  not available.
† P  0.05 versus the corresponding subgroup (i.e., non-OA control group or asymptomatic chondropathy group).
‡ P  0.001 versus the non-OA control group.
§ The total radiographic score is the sum of the scores for tibiofemoral joint space narrowing (JSN) and osteophytes.
¶ The total Mankin score is the sum of the scores for cartilage surface integrity, tidemark breaching, proteoglycan loss, and chondrocyte morphology.
Tidemark breaching is expressed as the percentage of subjects in whom cartilage integrity permitted assessment (25 in the advanced OA group and
24 in the symptomatic chondropathy group).
# P  0.01 versus the corresponding subgroup.
** Fractional areas are the percentage of the synovial area occupied by CD68-immunoreactive macrophages or nerve growth factor–immunoreactive
cells. Fractional areas are reported only for samples that displayed synovial lining (n  15–26 per group).
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stained with DAPI, and autofluorescence was blocked with 1%
Sudan black (Sigma-Aldrich) in 70% ethanol. Sections were
mounted in phosphate buffered saline/glycerol.
Image analysis. All histologic and immunohistologic
scoring was carried out by a single observer (LAS) who was
blinded with regard to the diagnostic group and clinical details.
A Zeiss Axioscop-50 microscope was used. Macrophage and
NGF fractional areas were quantified using a 3-CCD video
camera and KS300 image analysis software. Areas of the
synovium with the highest density of positive staining for CD68
or NGF were identified. Briefly, an image was captured, and
area of interest, which included the synovial lining and sublin-
ing, was delineated. Positive staining was differentiated from
background by thresholding the image according to hue in
order to create a mask. The area of positive staining and the
total area were measured. The fractional area was determined
as the percentage of synovial area positive for CD68 or NGF
immunoreactivity within the total area. Data were collected
using a 20 objective lens in 4 different fields of view. Only
samples with synovial lining were included in the analyses.
Statistical analysis. Data were analyzed using SPSS
v.21 software. The Mann-Whitney U test was used to compare
TKR and postmortem groups for each variable, except for age
(compared by t-tests) and the presence of subchondral bone
marrow replacement (compared by chi-square test) between
groups. Associations between BMI and outcome measures
were evaluated using linear regression, adjusting for age and
experimental group. Statistical significance was accepted when
the P value was less than 0.05. Logistic regression was used to
adjust for sex differences in the non-OA control and age-
matched advanced OA group comparisons and for age differ-
ences in the asymptomatic and symptomatic chondropathy
group comparisons.
The intraobserver reliability for the histology and
fractional area scores was assessed by rescoring 20–25 ran-
domly selected cases on 2 separate occasions 6 months apart.
For reproducibility analyses, the kappa statistic (StatsDirect
software) (27) was used for cartilage, subchondral bone, and
synovial scores. The intraclass correlation coefficient (SPSS
software) was used for the fractional area values.
Figure 1. Histopathologic features of non-osteoarthritic (non-OA) (A–D) and OA (E–J) knees. Non-OA knees typically displayed mild cartilage
surface irregularities of the superficial zone, with normal proteoglycan staining (A), whereas in some patients with advanced OA of the knee, there
were deep clefts in the articular cartilage surface and severe proteoglycan loss (E) (Safranin O–fast green stained). Channels can be seen in the
calcified cartilage beneath an intact tidemark in a non-OA knee (B), whereas an OA knee shows a channel breaching the tidemark and entering the
noncalcified cartilage (F) (hematoxylin and eosin [H&E] stained). Normal subchondral bone marrow spaces are filled with fatty tissue in a non-OA
knee (C), whereas subchondral bone marrow is replaced by fibrovascular tissue in an OA knee (G) (H&E stained). Mild synovial lining hyperplasia
is shown in a sample from a non-OA knee (D), whereas severe synovitis, characterized by hyperplasia and hypertrophy of the synovial lining and
sublining hypercellularity, can be seen in an OA knee (H) (H&E stained). Macrophage immunoreactivity for CD68 (I) and immunoreactivity for
nerve growth factor (J) in OA knees was localized to the synovial lining and sublining regions (staining [blue-black] developed with nickel-enhanced
diaminobenzidine). Arrows indicate the synovial surface. Bars  500 m.
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RESULTS
Histopathologic features of knee OA. Patient
demographics are reported in Table 1, and histopatho-
logic features are illustrated in Figure 1. Samples dis-
played a range of cartilage changes, including mild clefts
to the articular surface with normal proteoglycan con-
tent (Figure 1A), as compared with deep clefts and loss
of proteoglycan in some advanced OA cases (Figure
1E). Channels from the subchondral bone were found in
close proximity to the tidemark (Figure 1B) and also
breached the tidemark to invade the noncalcified carti-
lage (Figure 1F). Subchondral bone spaces mostly con-
tained normal fatty tissue (Figure 1C); however, in some
cases, this was replaced by fibrovascular tissue (Figure
1G). Synovial inflammation was sometimes marked, with
lining hyperplasia and lymphoid aggregates (Figure 1H).
CD68 (Figure 1I) and NGF (Figure 1J) cells were
evident in the synovial lining and sublining regions and
surrounded the blood vessels.
NGF immunoreactivity in the synovium was pre-
dominantly localized to Hsp47 spindle-shaped and
mononuclear cells, consistent with fibroblast morphol-
ogy (Figures 2A and B). However, some NGFHsp47–
and NGF–Hsp47 cells were also observed. Some
CD68macrophages in the lining and sublining regions
also displayed NGF immunoreactivity (Figures 2C and
D). Similar distributions were found in advanced OA
patients and non-OA controls.
Intraobserver reliability for histologic scoring was
moderate or substantial, as determined using the kappa
statistic (range 0.53–0.76). For fractional area measure-
ments, the intraclass correlation coefficient was 0.85,
indicating good reproducibility.
Patients with advanced OA displayed more se-
vere cartilage surface changes, proteoglycan loss, tide-
mark breaching, changes in chondrocyte phenotype, and
synovitis than did non-OA controls (P  0.05 for each
comparison) (Figure 3). Tidemark breaching was ob-
served in 17 of 25 (68%) of the advanced OA patients
and 9 of 26 (35%) of the non-OA controls (P  0.012).
Subchondral fibrovascular replacement was present in 5
of 26 (19%) of the advanced OA patients and was absent
from the non-OA controls; however, significance was
lost after adjusting for sex differences. The synovial
fractional areas positive for CD68 and NGF immuno-
reactivities were greater in patients with advanced OA
than in the non-OA controls (P  0.031 and 0.035,
respectively) (Figures 3E and F).
Histopathologic features of symptomatic knee
OA. Both the asymptomatic and symptomatic chondro-
pathy groups displayed evidence of structural OA, with
higher macroscopic chondropathy scores than the
non-OA controls (Table 1). Patients in the symptomatic
chondropathy group displayed macroscopic chondropa-
thy features similar to the subjects in the asymptomatic
chondropathy group, indicating appropriate matching
(Table 1). Severe macroscopic chondropathy lesions
graded as 3 or 4 (deep cartilage fibrillation or subchon-
dral bone exposure, respectively) were present in the
medial tibiofemoral compartment of 28 of 29 (97%)
subjects with asymptomatic chondropathy and 29 of 29
(100%) patients with symptomatic chondropathy.
Loss of cartilage surface integrity and alterations
in chondrocyte morphology were greater in the symp-
tomatic chondropathy group than in the asymptomatic
chondropathy group (Table 1 and Figures 4A and B),
whereas proteoglycan loss, tidemark integrity, and sub-
chondral bone marrow replacement by fibrovascular
tissue did not differ significantly between groups.
Figure 2. Cellular localization of nerve growth factor (NGF) immu-
noreactivity in human synovium. A, Hsp47 immunoreactivity localized
to cells with fibroblast morphology in the lining and sublining regions
of synovium from a patient with osteoarthritis (OA). Arrow indicates a
fibroblast colocalized to NGF (same cell as indicated in B); arrowhead
indicates a fibroblast not colocalized to NGF. B, NGF immunoreac-
tivity colocalized with Hsp47 (arrow) and in a cell that is not immuno-
labeled for Hsp47 (arrowhead) in the section shown in A. C, CD68
immunoreactivity of macrophages in synovium from a patient with
OA. Arrow indicates a macrophage colocalized to NGF (same cell as
indicated in D); arrowhead indicates a macrophage not colocalized to
NGF. D, NGF immunoreactivity colocalized with CD68 (arrow) and in
a cell that is not immunolabeled for CD68 (arrowhead) in the section
shown in C. Double immunohistochemistry was visualized by Texas
Red (Hsp47 and CD68 [red]) and fluorescein (NGF [green]) staining.
Dotted lines indicate the synovial surface. Bars  50 m.
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Figure 3. Histopathologic features of osteoarthritis (OA). Scatterplots illustrate the differences between the non-OA control group and the
advanced OA group for the scores on cartilage surface integrity (A), proteoglycan loss (B), chondrocyte morphology (C), and synovitis (D), and for
the synovial fractional area positive for CD68-immunoreactive macrophages (E) and nerve growth factor (NGF) (F). Each symbol represents an
individual subject; horizontal lines and error bars show the median and interquartile range.  P 0.05;  P 0.001 versus the non-OA control
group.
Figure 4. Histologic associations of symptomatic osteoarthritis (OA). Scatterplots illustrate the differences between subjects with similar
macroscopic chondropathy scores who did not (asymptomatic chondropathy) or did (symptomatic chondropathy) undergo total knee replacement
surgery. The cartilage surface integrity score (A), chondrocyte morphology score (B), synovitis score (C), and synovial fractional area positive for
nerve growth factor (NGF) (D) were greater in the symptomatic chondropathy group, but differences in the synovial fractional area positive for
CD68-immunoreactive macrophages (E) did not reach statistical significance. Each symbol represents an individual subject; horizontal lines and
error bars show the median and interquartile range.   P  0.05;   P  0.01 versus the asymptomatic chondropathy group.
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Synovitis scores were greater in patients in the
symptomatic chondropathy group than in subjects in
the asymptomatic chondropathy group (Table 1 and
Figure 4C). Severe inflammation with perivascular lym-
phoid aggregates was observed in 8 of 29 symptomatic
chondropathy patients (28%) compared with 1 of 29
asymptomatic chondropathy subjects (3%) (P  0.021).
The synovial area positive for NGF was greater in
symptomatic chondropathy patients than in asymptom-
atic chondropathy patients (Table 1 and Figure 4D).
Differences in macrophage infiltration between groups
did not reach statistical significance (Table 1 and Figure
4E). We used logistic regression analysis to examine
whether the association between symptomatic OA and
synovitis was explained by increased synovial NGF im-
munoreactivity and/or macrophage fractional area. As-
sociations between synovitis and symptomatic chondrop-
athy remained significant in each regression model
(P  0.008).
BMI (kg/m2) was calculated for both TKR groups
(advanced OA and symptomatic chondropathy). Data
were available for 42 of 54 patients (78%). Of these,
29 patients (69%) were classified as obese (BMI 30),
11 patients (26%) were classified as overweight (BMI
25–29.9), and 2 patients (5%) were a healthy weight
(BMI 18.5–24.9). Linear regression was used to deter-
mine associations between BMI and outcome measures,
combining data from both TKR groups. Age and exper-
imental group were used as independent covariates.
BMI was not significantly associated with any histo-
pathologic or immunohistologic parameter.
DISCUSSION
We found that a range of histopathologic features
in the synovium and tibial plateaus were associated with
OA. Of these, synovitis, increased synovial NGF immu-
noreactivity, chondrocyte changes, and loss of cartilage
surface integrity were associated with symptomatic OA,
as compared with postmortem subjects with similar
macroscopic joint surface appearances who had not
sought TKR during life. Increased synovitis and synovial
NGF expression by fibroblasts and some macrophages
may be key features associated with pain in OA.
The prevalence and severity of OA are strongly
associated with increasing age, raising doubts in earlier
studies as to whether the histopathologic features are
specifically associated with OA, rather than being char-
acteristics of healthy aging. We addressed this by care-
fully age-matching the patients with advanced OA and
the non-OA controls, a process that required a large
source repository from which to select cases.
Synovitis, the densities of CD68-immunoreactive
macrophages or NGF-immunoreactive cells within the
synovium, proteoglycan loss, chondrocyte changes, loss
of tidemark integrity, and tidemark breaching were all
greater in patients with advanced OA than in age-
matched non-OA controls. This finding indicates that in
this study, these pathologic features of OA were not
explained by aging alone. However, each of these fea-
tures was also observed to a lesser extent in our age-
matched control group, indicating the presence of either
“preclinical” early OA in the control group or the
presence of normal structural features in the advanced
OA group that are exaggerated by the disease. A key
question, therefore, is which pathologic features are
associated with clinical OA?
The relevance of structural changes to OA symp-
toms has been difficult to determine. Evidence of syno-
vitis on magnetic resonance imaging (MRI) has been
associated with pain in people who have OA or those
who are at high risk of developing OA (5). Furthermore,
a recent study demonstrated that fluctuation in synovitis
corresponds to a fluctuation in knee pain, providing
further evidence of the contribution of synovitis to
symptomatic OA (28). Patients with greater amounts of
synovitis display more severe chondropathy, and synovi-
tis may predict progressive structural damage in knee
OA (22,29). It can therefore be difficult to be certain as
to whether synovitis itself is a cause of pain or whether
it acts as a surrogate for other aspects of OA pathology.
Our work extends these previous findings by indicating
that synovitis is associated with symptomatic OA inde-
pendently of the severity of chondropathy.
In the present study, we explored the character-
istics of synovitis that have been associated with symp-
tomatic OA. We confirmed the previous findings of
increased macrophage infiltration in OA (10), but the
presence of macrophages may not be sufficient to ex-
plain OA pain. Levels of NGF are elevated in the
synovial fluid of patients with rheumatoid arthritis
(16,30), and NGF is present to a lesser extent in patients
with OA (17), but a previous study did not localize NGF
to the synovium in the single OA case reported (31).
Nevertheless, monoclonal antibodies directed against
NGF have been shown to reduce pain and improve
function in people with OA (13–15).
We showed that in OA, NGF immunoreactivity is
present in the synovium, predominantly in Hsp47
fibroblasts, and in some macrophages. NGF immuno-
reactivity was greater in the synovial tissue of the
symptomatic chondropathy group than in that of the
asymptomatic chondropathy group. These findings sug-
gest an important contribution of fibroblast-derived
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NGF in the generation of OA pain. The proinflam-
matory cytokines interleukin-1 and tumor necrosis
factor  (TNF) can stimulate the release of NGF
from synovial fibroblasts, and NGF can modulate the
release of TNF (18). NGF may act on sensory nerves to
increase pain in OA. After we adjusted for NGF and/or
CD68 immunoreactivity, the significant association of
synovitis with symptomatic OA remained, suggesting
that increased NGF and macrophage infiltration, either
alone or together, do not completely explain the pain.
The production of pain mediators, for example, by
fibroblasts, may yet be driven by macrophages or other
aspects of inflammation.
Previous histopathologic studies of OA have of-
ten relied on samples obtained at joint replacement
surgery, which display a range of OA structural severity
(22). The severity of chondropathy overlaps to a small
extent between postmortem cases and surgical cases
(22), and therefore, our study of pathologic associations
in symptomatic OA required selection of cases with
matched degrees of macroscopic chondropathy from a
large tissue repository. Radiographic scores in our symp-
tomatic chondropathy group were similar to those in our
advanced OA group, and macroscopic chondropathy
scores in the symptomatic and asymptomatic chondrop-
athy groups were significantly higher than those in the
non-OA control group, indicating that both of the chon-
dropathy groups had pathologic features of knee OA.
Although the two chondropathy groups were
matched for similarity of macroscopic chondropathy
scores, microscopic loss of cartilage surface integrity was
greater in the symptomatic chondropathy group. Chon-
dropathy cases were selected on the basis of similar total
macroscopic chondropathy scores of the tibiofemoral
joint, where the appearance of the 4 articular surfaces
was evaluated: the medial and lateral femoral condyle
and tibial plateau. Histologic grading was examined in
one midcoronal section of the middle one-third of the
medial tibial plateau because this is an important
weight-bearing area that is characteristically affected by
OA. Macroscopic and microscopic analyses therefore
reflect distinct but related aspects of OA pathology (22).
Not all histopathologic features associated with
OA were associated with symptomatic OA. Tidemark
breaching was found in twice as many asymptomatic
chondropathy cases than non-OA controls, suggesting
that it may be an early feature of OA, but it was no more
common in the symptomatic chondropathy group than
the asymptomatic chondropathy group. In contrast, os-
teochondral vascularity was previously associated with
pain behavior in rats with OA following transection of
the medial meniscus (32). Our current data suggest that
tidemark breaching alone is insufficient to cause OA
symptoms and that additional factors, such as sensory
innervation or local expression of NGF, may be neces-
sary mediators of pain from osteochondral channels
(12). Our current study provides novel insights into the
incidence of tidemark breaching in a subgroup of asymp-
tomatic postmortem cases with macroscopic chondrop-
athy similar to patients who underwent TKR. Further
work would be required to determine the time course
and mechanisms by which channels breaching the tide-
mark may predispose to pain.
Fibrovascular replacement of the subchondral
bone marrow was twice as common in the symptomatic
chondropathy group as it was in the asymptomatic
chondropathy group, but this difference did not reach
statistical significance after adjusting for age differences
between groups. Bone marrow replacement has been
associated with bone marrow lesions on MRI (33), which
in turn, has been associated with pain in knee OA (7,34).
Our study may have had insufficient power to detect
differences between groups, and further work would be
required to define the structural and biochemical fea-
tures of bone marrow lesions that may explain their
association with pain.
Obesity is a major risk factor for OA (35–37) and
has been associated with pain (38) and cartilage changes
(39,40). The majority of patients with advanced OA in
our cohort were classified as overweight or obese, but
histopathologic factors associated with symptoms were
not significantly associated with BMI in our study.
Our study is necessarily subject to a number of
limitations. We assumed that the subjects in the asymp-
tomatic chondropathy group had experienced less pain
than the patients in the symptomatic chondropathy
group, since to the best of our knowledge, these subjects
had not sought medical attention for knee pain during
the last year of life. Clinical data acquisition in postmor-
tem cases relies on case notes, where knee pain may not
have been reported, and interviews with bereaved rela-
tives, who may not have been aware of the deceased’s
symptoms. Histologic analysis was performed on only 1
section of osteochondral tissue per case, and the sample
was obtained from the midcoronal section of the middle
one-third of the medial tibial plateau, a key weight-
bearing site. It is possible that there may be different
structural associations with symptoms at other sites
within the joint. Furthermore, our patients with symp-
tomatic OA all had late-stage disease (undergoing
TKR), and different structural features may be associ-
ated with pain in early OA.
Our study design avoided confounding by age in
our characterization of features associated with OA, but
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we were unable to simultaneously match for sex. Simi-
larly, matching for the severity of chondropathy pre-
cluded age matching between our symptomatic and
asymptomatic chondropathy groups, even when using a
source repository containing samples from1,700 cases.
However, we adjusted for age or sex differences in our
analyses.
We classified postmortem cases as having OA
based on the presence of cartilage changes comparable
to those seen in patients undergoing TKR for OA, and
we selected small, homogeneous patient groups in order
to undertake detailed histopathologic experiments. Our
work extends imaging and arthroscopic studies indicat-
ing the relative importance of synovitis (3,5) and mac-
roscopic cartilage changes (41,42) to symptoms in the
broader OA population.
We have identified histopathologic features of
knee joint tissues that are associated with OA; however,
not all of these features may cause pain. Symptomatic
OA was associated with synovitis, synovial NGF immu-
noreactivity, changes in chondrocyte morphology, and
loss of cartilage surface integrity as compared with
the asymptomatic chondropathy group showing a simi-
lar macroscopic joint surface appearance who had
not sought TKR during life. Different pathologic fea-
tures of OA typically coincide, and better understanding
of the structural features that are associated with symp-
tomatic OA would help in refining strategies for devel-
oping structure-modifying treatments (disease-modifying
OA drugs) by focusing on those which are most likely
to improve symptoms. Synovitis and synovial NGF ex-
pressed by fibroblasts and some macrophages may be
key mediators associated with OA knee pain.
ACKNOWLEDGMENTS
We are grateful to the patients, orthopedic surgeons,
and Bereavement Centre colleagues at Sherwood Forest Hos-
pitals NHS Foundation Trust for providing the postmortem
and surgical tissue for our repository. We thank the staff of the
Histopathology Department at Sherwood Forest Hospitals
NHS Foundation Trust for processing the tissues.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Ms Stoppiello had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Stoppiello, Mapp, Wilson, Hill,
Scammell, Walsh.
Acquisition of data. Stoppiello.
Analysis and interpretation of data. Stoppiello, Mapp, Scammell,
Walsh.
REFERENCES
1. Bedson J, Croft PR. The discordance between clinical and radio-
graphic knee osteoarthritis: a systematic search and summary of
the literature. BMC Musculoskelet Disord 2008;9:116.
2. Dieppe PA, Cushnaghan J, Shepstone L. The Bristol ‘OA500’
study: progression of osteoarthritis (OA) over 3 years and the
relationship between clinical and radiographic changes at the knee
joint. Osteoarthritis Cartilage 1997;5:87–97.
3. Hill CL, Hunter DJ, Niu J, Clancy M, Guermazi A, Genant H, et
al. Synovitis detected on magnetic resonance imaging and its
relation to pain and cartilage loss in knee osteoarthritis. Ann
Rheum Dis 2007;66:1599–603.
4. Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME,
et al. Knee effusions, popliteal cysts, and synovial thickening:
association with knee pain in osteoarthritis. J Rheumatol 2001;28:
1330–7.
5. Baker K, Grainger A, Niu J, Clancy M, Guermazi A, Crema M, et
al. Relation of synovitis to knee pain using contrast-enhanced
MRIs. Ann Rheum Dis 2010;69:1779–83.
6. Torres L, Dunlop DD, Peterfy C, Guermazi A, Prasad P, Hayes
KW, et al. The relationship between specific tissue lesions and
pain severity in persons with knee osteoarthritis. Osteoarthritis
Cartilage 2006;14:1033–40.
7. Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME,
Skinner KM, et al. The association of bone marrow lesions with
pain in knee osteoarthritis. Ann Intern Med 2001;134:541–9.
8. Szebenyi B, Hollander AP, Dieppe P, Quilty B, Duddy J, Clarke S,
et al. Associations between pain, function, and radiographic
features in osteoarthritis of the knee. Arthritis Rheum 2006;54:
230–5.
9. Hernandez-Molina G, Neogi T, Hunter DJ, Niu J, Guermazi A,
Reichenbach S, et al. The association of bone attrition with knee
pain and other MRI features of osteoarthritis. Ann Rheum Dis
2008;67:43–7.
10. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan
B. Synovial tissue inflammation in early and late osteoarthritis.
Ann Rheum Dis 2005;64:1263–7.
11. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A,
Wilson D, et al. Inflammation and angiogenesis in osteoarthritis.
Arthritis Rheum 2003;48:2173–7.
12. Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Franses RE,
Mapp PI, et al. Angiogenesis and nerve growth factor at the
osteochondral junction in rheumatoid arthritis and osteoarthritis.
Rheumatology (Oxford) 2010;49:1852–61.
13. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West
CR. Tanezumab reduces osteoarthritic knee pain: results of a
randomized, double-blind, placebo-controlled phase III trial. J
Pain 2012;13:790–8.
14. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL,
Smith MD, et al. Tanezumab for the treatment of pain from
osteoarthritis of the knee. N Engl J Med 2010;363:1521–31.
15. Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, et
al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve
growth factor antibody, in the treatment of patients with moderate
to severe osteoarthritis pain. Pain 2013;154:1910–9.
16. Halliday DA, Zettler C, Rush RA, Sciccitano R, McNeil JD.
Elevated nerve growth factor levels in the synovial fluid of patients
with inflammatory joint disease. Neurochem Res 1998;23:919–22.
17. Barthel C, Yeremenko N, Jacobs R, Schmidt RE, Bernateck M,
Zeidler H, et al. Nerve growth factor and receptor expression in
rheumatoid arthritis and spondyloarthritis. Arthritis Res Ther
2009;11:R82.
18. Manni L, Lundeberg T, Fiorito S, Bonini S, Vigneti E, Aloe L.
Nerve growth factor release by human synovial fibroblasts prior to
and following exposure to tumor necrosis factor-, interleukin-1
and cholecystokinin-8: the possible role of NGF in the inflamma-
tory response. Clin Exp Rheumatol 2003;21:617–24.
19. Izquierdo E, Canete JD, Celis R, Del Rey MJ, Usatequi A, Marsal
3026 STOPPIELLO ET AL
S, et al. Synovial fibroblast hyperplasia in rheumatoid arthritis:
clinicopathologic correlations and partial reversal by anti–tumor
necrosis factor therapy. Arthritis Rheum 2011;63:2575–83.
20. Holness CL, Simmons D. Molecular cloning of CD68, a human
macrophage marker related to lysosomal glycoproteins. Blood
1993;81:1607–13.
21. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K,
et al. Development of criteria for the classification and reporting
of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039–49.
22. Walsh DA, Yousef A, McWilliams DF, Hill R, Hargin E, Wilson
D. Evaluation of a Photographic Chondropathy Score (PCS) for
pathological samples in a study of inflammation in tibiofemoral
osteoarthritis. Osteoarthritis Cartilage 2009;17:304–12.
23. Ayral X, Gueguen A, Listrat V, Bahuaud J, Beaufils P, Beguin J,
et al. Simplified arthroscopy scoring system for chondropathy of
the knee (revised SFA score). Rev Rhum [Engl Ed] 1994;61:88–90.
24. Nagaosa Y, Mateus M, Hassan B, Lanyon P, Doherty M. Devel-
opment of a logically devised line drawing atlas for grading of knee
osteoarthritis. Ann Rheum Dis 2000;59:587–95.
25. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and
metabolic abnormalities in articular cartilage from osteo-arthritic
human hips. II. Correlation of morphology with biochemical and
metabolic data. J Bone Joint Surg Am 1971;53:523–37.
26. Shu S, Ju G, Fan L. The glucose oxidase-DAB-nickel method in
peroxidase histochemistry of the nervous system. Neurosci Lett
1988;85:169–71.
27. Viera A, Garrett J. Understanding interobserver agreement: the
kappa statistic. Fam Med 2005;37:360–3.
28. Zhang Y, Nevitt M, Niu J, Lewis C, Torner J, Guermazi A, et al.
Fluctuation of knee pain and changes in bone marrow lesions,
effusions, and synovitis on magnetic resonance imaging. Arthritis
Rheum 2011;63:691–9.
29. Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados
M. Synovitis: a potential predictive factor of structural progression
of medial tibiofemoral knee osteoarthritis: results of a 1 year
longitudinal arthroscopic study in 422 patients. Osteoarthritis
Cartilage 2005;13:361–7.
30. Raychaudhuri SP, Raychaudhuri SK, Atkuri KR, Herzenberg LA,
Herzenberg LA. Nerve growth factor: a key local regulator in the
pathogenesis of inflammatory arthritis. Arthritis Rheum 2011;63:
3243–52.
31. Aloe L, Tuveri MA, Carcassi U, Levi-Montalcini R. Nerve growth
factor in the synovial fluid of patients with chronic arthritis.
Arthritis Rheum 1992;35:351–5.
32. Mapp PI, Walsh DA, Bowyer J, Maciewicz RA. Effects of a
metalloproteinase inhibitor on osteochondral angiogenesis, chon-
dropathy and pain behavior in a rat model of osteoarthritis.
Osteoarthritis Cartilage 2010;18:593–600.
33. Zanetti M, Bruder E, Romero J, Hodler J. Bone marrow edema
pattern in osteoarthritic knees: correlation between MR imaging
and histologic findings. Radiology 2000;215:835–40.
34. Felson DT, Niu J, Guermazi A, Roemer F, Aliabadi P, Clancy M,
et al. Correlation of the development of knee pain with enlarging
bone marrow lesions on magnetic resonance imaging. Arthritis
Rheum 2007;56:2986–92.
35. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF.
Obesity and knee osteoarthritis: the Framingham Study. Ann
Intern Med 1988;109:18–24.
36. Ackerman IN, Osborne RH. Obesity and increased burden of hip
and knee joint disease in Australia: results from a national survey.
BMC Musculoskelet Disord 2012;13:254.
37. Jiang L, Tian W, Wang Y, Rong J, Bao C, Liu Y, et al. Body mass
index and susceptibility to knee osteoarthritis: a systematic review
and meta-analysis. Joint Bone Spine 2012;79:291–7.
38. Goulston LM, Kiran A, Javaid MK, Soni A, White KM, Hart DJ,
et al. Does obesity predict knee pain over fourteen years in
women, independently of radiographic changes? Arthritis Care
Res (Hoboken) 2011;63:1398–406.
39. Roemer FW, Zhang Y, Niu J, Lynch JA, Crema MD, Marra MD,
et al, for the Multicenter Osteoarthritis (MOST) Study Investiga-
tors. Tibiofemoral joint osteoarthritis: risk factors for MR-
depicted fast cartilage loss over a 30-month period in the Multi-
center Osteoarthritis Study. Radiology 2009;252:772–80.
40. Antony B, Ding C, Stannus O, Cicuttini F, Jones G. Association of
baseline knee bone size, cartilage volume, and body mass index
with knee cartilage loss over time: a longitudinal study in younger
or middle-aged adults. J Rheumatol 2011;38:1973–80.
41. Hunter DJ, March L, Sambrook PN. The association of cartilage
volume with knee pain. Osteoarthritis Cartilage 2003;11:725–9.
42. Sowers MF, Hayes C, Jamadar D, Capul D, Lachance L, Jan-
nausch M, et al. Magnetic resonance-detected subchondral bone
marrow and cartilage defect characteristics associated with pain
and X-ray-defined knee osteoarthritis. Osteoarthritis Cartilage
2003;11:387–93.
STRUCTURAL ASSOCIATIONS OF SYMPTOMATIC KNEE OA 3027
